SEC Tracker
Get the app

X4 Pharmaceuticals XFOR

X4 Pharmaceuticals reported a $20.2 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $2.8 million for the three months ended Sep 30, 2026.
  2. Diluted EPS was -$0.16 for the three months ended Sep 30, 2026.
  3. Cash and equivalents were $185.8 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when X4 Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, X4 Pharmaceuticals, Inc reported: Revenue $2.9 million.
  • Net income -$20.2 million.
  • Gross margin 82.2%.
  • Operating margin -694.4%.
  • Net margin -701.6%.
  • Revenue change from a year earlier +63.1%.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  2. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  3. Pluri PLUR public float $15M, Dec 31, 2025
  4. CalciMedica CALC public float $16M, Jun 30, 2025
  5. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old